Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study
| العنوان: | Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study |
|---|---|
| المؤلفون: | Masao Nawata, Satoshi Kubo, Kazuyoshi Saito, Shunsuke Fukuyo, Yasushi Mizuno, Kunihiro Yamaoka, Yoshiya Tanaka, Shigeru Iwata, Norifumi Sawamukai, Shintaro Hirata |
| المصدر: | Modern Rheumatology. 24:42-51 |
| بيانات النشر: | Oxford University Press (OUP), 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Male, musculoskeletal diseases, medicine.medical_specialty, Immunoconjugates, genetic structures, Hand Joints, Arthritis, Severity of Illness Index, Abatacept, Arthritis, Rheumatoid, Disability Evaluation, Rheumatology, Foot Joints, Internal medicine, Severity of illness, medicine, Humans, Aged, Retrospective Studies, biology, business.industry, C-reactive protein, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Surgery, Radiography, C-Reactive Protein, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Orthopedic surgery, Disease Progression, biology.protein, Female, Matrix Metalloproteinase 3, business, medicine.drug |
| الوصف: | Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA).Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice.At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections.Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice. |
| تدمد: | 1439-7609 1439-7595 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91381b84383e0683a18cb8154a8a2442 https://doi.org/10.3109/14397595.2013.854051 |
| رقم الأكسشن: | edsair.doi.dedup.....91381b84383e0683a18cb8154a8a2442 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. 
PDF full text from Publisher | تدمد: | 14397609 14397595 |
|---|